Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on May 15, 2017, 10:04:23 am
-
Liver fat content does not drive disease progression among people with non-alcoholic steatohepatitis (NASH); rather, fibrosis, or scarring of the organ, is the culprit, MedPage Today reports. Researchers reached this conclusion during otherwise failed placebo-controlled trials of a treatment for NASH, the cloned antibody simtuzumab.
Between the two trials, investigators enrolled 477 people with NASH, including 219 people with bridging fibrosis and 258 with cirrhosis, to receive a planned 240 weeks of simtuzumab.
At the 96-week mark of the trials, the treatment showed no efficacy and the studies were discontinued.
Read more...
https://www.hepmag.com/article/liver-fat-true-culprit-behind-nashrelated-disease-progression